MAR
33
-2
CTAS
37
-3
HOG
43
-2
MSFT
53
3
SBUX
41
-4
LLY
59
2
FLR
46
6
MLM
51
-2
FRT
45
-3
CLX
53
-2
KR
61
2
AFL
60
-2
VZ
54
2
NAVI
27
-2
GM
65
15
TAP
60
2
A
43
2
PFG
39
-11
IVZ
39
6
UPS
32
-3
MAR
33
-2
CTAS
37
-3
HOG
43
-2
MSFT
53
3
SBUX
41
-4
LLY
59
2
FLR
46
6
MLM
51
-2
FRT
45
-3
CLX
53
-2
KR
61
2
AFL
60
-2
VZ
54
2
NAVI
27
-2
GM
65
15
TAP
60
2
A
43
2
PFG
39
-11
IVZ
39
6
UPS
32
-3
Financhill
Back

PTC Therapeutics 10K Form

Sell
43

PTCT
PTC Therapeutics

Last Price:
$57.10
Seasonality Move:
12.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-25 10Q PTCT/PTC Therapeutics Quarterly
2023-10-26 10Q PTCT/PTC Therapeutics Quarterly
2023-08-03 10Q PTCT/PTC Therapeutics Quarterly
2023-04-27 10Q PTCT/PTC Therapeutics Quarterly
2022-10-27 10Q PTCT/PTC Therapeutics Quarterly
2022-08-04 10Q PTCT/PTC Therapeutics Quarterly

Receive PTCT News And Ratings

See the #1 stock for the next 7 days that we like better than PTCT

PTCT Financial Statistics

Sales & Book Value

Annual Sales: $806.8M
Cash Flow: $-36.5M
Price / Cash Flow: 0
Annual Sales: $-14.13
Price / Book: 0

Profitability

EPS (TTM): -4.73000
Net Income (TTM): $-363.3M
Gross Margin: $749.4M
Return on Equity: 0%
Return on Assets: -19.86%

PTC Therapeutics Earnings Forecast

Key PTC Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for PTCT is 92.89%.
  • The Selling, General & Administrative Expenses for PTCT have been equal to 37.30% of Gross Profit Margin.
  • The Research & Development expenses have been 66.25% of Revenue.
  • The Net Earning history of PTCT is -45.03% of Total Revenues.
  • Per Share Earnings over the last 14 years have been positive in 5 years.

PTC Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PTCT
CUSIP: 69366J
Website: ptcbio.com

Debt

Debt-to-Equity Ratio: -2.16
Current Ratio: 2.35
Quick Ratio: 2.23

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PTCT Technical Analysis vs Fundamental Analysis

Sell
43
PTC Therapeutics (PTCT) is a Sell

Is PTC Therapeutics a Buy or a Sell?

  • PTC Therapeutics stock is rated a Sell
    The current PTC Therapeutics [PTCT] share price is $57.14. The Score for PTCT is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.